Promotes CRC progression,increases expression of downstream oncogenic target genes, FAK, IGF1R, EGFR, and YY1 that activate PI3K/AKT and MEK/ERK signaling pathways to promote cancer progression and drug resistance. This evidence concerns the gene PTK2 and colorectal carcinoma.